Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...
Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback